CVE-2026-21923: Oracle Life Sciences SQL Injection Flaw

CVE-2026-21923 Overview

A vulnerability exists in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). This easily exploitable flaw allows an unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful exploitation can result in unauthorized update, insert, or delete access to some accessible data, as well as unauthorized read access to a subset of data within the application.

Critical Impact

Unauthenticated remote attackers can gain unauthorized read and write access to sensitive healthcare and life sciences data without requiring any privileges or user interaction.

Affected Products

• Oracle Life Sciences Central Designer version 7.0.1.0
• Oracle Health Sciences Applications (Platform component)

Discovery Timeline

• January 20, 2026 - CVE-2026-21923 published to NVD
• January 20, 2026 - Last updated in NVD database

Technical Details for CVE-2026-21923

Vulnerability Analysis

This vulnerability in Oracle Life Sciences Central Designer affects the Platform component and is characterized by its ease of exploitation. The flaw allows unauthenticated attackers to access the application remotely over HTTP without requiring any user interaction or special privileges. The vulnerability impacts both data confidentiality and integrity, enabling attackers to read sensitive information and modify data within the application's accessible scope.

The attack complexity is low, meaning that readily available techniques can be used to exploit this vulnerability. Since the attack vector is network-based and requires no authentication, any system exposing the vulnerable Oracle Life Sciences Central Designer instance to the network is at risk.

Root Cause

The root cause of this vulnerability lies in improper access control within the Platform component of Oracle Life Sciences Central Designer. The application fails to properly validate authentication before allowing access to certain data operations, enabling unauthenticated users to perform read, insert, update, and delete operations on accessible data stores.

Attack Vector

The attack vector for CVE-2026-21923 is network-based, specifically over HTTP. An attacker can remotely target vulnerable Oracle Life Sciences Central Designer instances without requiring valid credentials. The attack does not require user interaction, making it suitable for automated exploitation attempts.

The vulnerability can be exploited by sending specially crafted HTTP requests to the vulnerable Platform component. Due to insufficient authentication enforcement, the application processes these requests and returns or modifies data that should be protected.

Detection Methods for CVE-2026-21923

Indicators of Compromise

• Unusual HTTP requests to Oracle Life Sciences Central Designer endpoints from unauthenticated sources
• Unexpected data modifications or insertions in the application database
• Anomalous read patterns accessing sensitive life sciences data
• Access attempts from unfamiliar IP addresses targeting the Platform component

Detection Strategies

• Monitor HTTP access logs for requests to Oracle Life Sciences Central Designer from unauthenticated sessions
• Implement network intrusion detection rules to identify suspicious request patterns targeting the Platform component
• Deploy web application firewalls (WAF) with rules specific to Oracle Health Sciences Applications
• Review audit logs for unauthorized data access or modification events

Monitoring Recommendations

• Enable detailed logging for all Oracle Life Sciences Central Designer access events
• Configure alerting for authentication bypass attempts and unauthorized data operations
• Monitor network traffic to and from Oracle Health Sciences Applications infrastructure
• Implement database activity monitoring to detect unauthorized queries and data changes

How to Mitigate CVE-2026-21923

Immediate Actions Required

• Apply the Oracle Critical Patch Update from January 2026 immediately
• Restrict network access to Oracle Life Sciences Central Designer to trusted sources only
• Implement network segmentation to isolate Oracle Health Sciences Applications
• Review and audit all recent data access and modification logs for signs of compromise

Patch Information

Oracle has released a security patch addressing this vulnerability as part of the Oracle Critical Patch Update January 2026. Organizations running Oracle Life Sciences Central Designer version 7.0.1.0 should apply the patch immediately to remediate this vulnerability.

Workarounds

• Implement strict firewall rules to limit HTTP access to Oracle Life Sciences Central Designer to authorized IP addresses only
• Deploy a reverse proxy with authentication requirements in front of the vulnerable application
• Enable IP-based access control lists (ACLs) to restrict access to trusted networks
• Consider temporarily taking the affected system offline until the patch can be applied if the risk is deemed unacceptable